Exploring the role of the microbiome and probiotics – what every pharmacist needs to know - Certificate of Completion
The human microbiome is increasingly being shown to influence health and disease and for this reason is often referred to as the ‘forgotten organ’. All the surfaces of the human body exposed to the environment, including the skin, gastrointestinal and respiratory systems and urogenital tract are colonised with microorganisms.The microbiome refers to the full complement of microbes (including bacteria, viruses, fungi and protozoa), their genes, genomes and their surrounding environmental conditions. Microbiota diversity describes the quantity of different species present and provides an indication on how evenly they are distributed within the community. In general, high microbial diversity is associated with a healthy gut microbiota while low diversity is considered a marker of dysbiosis (microbial imbalance) in the gut and has been implicated in autoimmune disease, obesity, gastrointestinal and cardio-metabolic conditions
This interactive online learning activity is valued at 1.5Hour(s) of continuing education.
Andrew Stewart Day
PhD, MB, ChB, MD, FRACP
Sydney Children’s Hospital, NSW, AU
Christchurch Hospital, Christchurch, NZ
Conjoint Professor, University of New South Wales, NSW, AU
Professor, University of Otago Christchurch, Christchurch, NZ
B.Pharm (Hons),PhD, GCResComm, GradCertAcadPract, AACPA, MPS
Course Coordinator and Lecturer
Discipline of Pharmacy
School of Clinical Sciences, Faculty of Health,
Queensland University of Technology, Brisbane, QLD
Direct Chemist Outlet, QLD
On completion of this program, participants will be better able to:
- Appraise the impact of biosimilar infliximab on the management of inflammatory bowel disease (IBD) based on recently-published clinical data.
- Outline clinical considerations when selecting biosimilar infliximab for patients with inflammatory bowel disease, including relevant safety and efficacy data and prescribing requirements.
- Recall and discuss the available evidence on switching from originator infliximab to biosimilar or from one biosimilar infliximab product to other biosimilar infliximab products.